Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kangfuyan Capsules is a Traditional Chinese Medicine (TCM) product developed and marketed by Shanxi Buchang Pharmaceutical. It is approved in China for the treatment of various gynecological inflammatory conditions, including chronic pelvic inflammatory disease (PID), adnexitis, and endometritis. The formulation is composed of multiple herbal ingredients, such as *Taraxacum mongolicum* (Dandelion), *Patrinia villosa*, *Paeonia lactiflora* (Red Peony Root), and *Angelica sinensis*. These components work synergistically to clear heat, remove toxins, and promote blood circulation to resolve blood stasis. Clinically, it is used to reduce inflammation, alleviate pelvic pain, and manage abnormal vaginal discharge, often serving as a complementary or primary treatment for reproductive tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kangfuyan Capsules.